SAFETY DATA SHEET
EQUIMAX®
(ivermectin 1.87%/praziquantel 14.03%)
Paste

1. IDENTIFICATION

Product Name	EQUIMAX® (ivermectin 1.87%/praziquantel 14.03%) Paste
Recommended use of the chemical and restrictions on use	
Identified uses	Worm control for horses and ponies
Restrictions on Use	Not for human use.
Company Identification	Virbac AH, Inc. P.O. Box 162059 Fort Worth, Texas 76161
Customer Information Number	(800) 338-3659
Emergency Telephone Number	
Chemtrec Number	(800) 424-9300
Other Emergency Number:	Human Toll-free 833-224-2009 Animal Toll-free 833-224-2013
Issue Date	March 3, 2020
Supersedes Date	December 21, 2015

Safety Data Sheet prepared in accordance with OSHA's Hazard Communication Standard (29 CFR 1910.1200) and the Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

2. HAZARDS IDENTIFICATION

Hazard Classification
Acute Hazards to the Aquatic Environment – Category 1 (This classification not adopted by OSHA.)

Label Elements
Hazard Symbols

Signal Word: Warning

Hazard Statements
Very toxic to aquatic life.

Precautionary Statements
Prevention
Avoid release to the environment.
Response
None
Storage
None
Disposal
Dispose of contents/container in accordance with local regulation.

2. HAZARDS IDENTIFICATION

Other Hazards
None

Specific Concentration Limits
The values listed below represent the percentages of ingredients of unknown toxicity.

Acute oral toxicity	0%
Acute dermal toxicity	<10%
Acute inhalation toxicity	<10%
Acute aquatic toxicity	10 - 20%

3. COMPOSITION/INFORMATION ON INGREDIENTS

Synonyms:
This product is a mixture.

Component Name	CAS Number	Concentration
Praziquantel	55268-74-1	14.03%
Ivermectin	70288-86-7	1.87%
Titanium Dioxide	13463-67-7	1 - 5%

4. FIRST AID MEASURES

Description of necessary first-aid measures
Eyes
Immediately flood the eye with plenty of water for at least 15-20 minutes, holding the eye open. Obtain medical attention if soreness or redness persists.
Skin
Wash skin thoroughly with soap and water. Obtain medical attention if redness or soreness persists.
Ingestion
Call a poison control center or doctor immediately for treatment advice. Do not induce vomiting unless told to do so by a poison control center or doctor. Do not give anything by mouth to an unconscious person.
Inhalation
Remove person to fresh air. Seek medical attention if symptoms persist.

Most important symptoms/effects, acute and delayed
Aside from the information found under Description of necessary first aid measures (above) and Indication of immediate medical attention and special treatment needed, no additional symptoms and effects are anticipated.

Indication of immediate medical attention and special treatment needed
Notes to Physicians
Treat symptomatically.

5. FIRE - FIGHTING MEASURES

Extinguishing Media
Use extinguishing media appropriate for surrounding materials.

5. FIRE - FIGHTING MEASURES

Unusual Fire and Explosion Hazards
Can release hazardous vapors during a fire.

Protective Equipment for Fire-Fighting
Wear full protective clothing and self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures
Wear appropriate protective clothing.

Environmental Precautions
Prevent the material from entering drains or watercourses.

Methods and materials for containment and cleaning up
Wipe up and transfer into suitable containers for recovery or disposal.

7. HANDLING AND STORAGE

Precautions for safe handling
Wear appropriate protective clothing. Wash hands after dispensing to dog and before eating, drinking or smoking.

Conditions for safe storage
Store in original container at room temperature 25˚C/77˚F with excursions permitted between 59˚F and 86˚F (15˚C - 30˚ C). Keep out of sunlight. Keep away from children.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Control parameters
Exposure limits are listed below, if they exist.

Praziquantel
None established
Ivermectin
None established
Titanium Dioxide
ACGIH TLV: 10 mg/m^3 TWA
OSHA PEL: 15 mg/m^3 TWA (Total dust)

Appropriate engineering controls
No specific measures necessary. Good general room ventilation is expected to be adequate to control airborne levels.

Individual protection measures
Respiratory Protection
Not required under normal conditions of use.
Skin Protection
Protective gloves.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Eye/Face Protection
Not required under normal conditions of use.
Body Protection
Normal work wear.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

Physical State	Solid (paste)
Color	White
Odor	None
Odor Threshold	No data available
pH	Not applicable
Density	No data available
Boiling Range/Point (°C/F)	Not applicable
Melting Point (°C/F)	Not applicable
Flash Point (PMCC) (°C/F)	Not flammable
Vapor Pressure	Not applicable
Evaporation Rate (BuAc=1)	Not applicable
Solubility in Water	No data available
Vapor Density (Air = 1)	Not applicable
VOC	Not applicable
Partition coefficient (n-octanol/water)	Not applicable
Viscosity	Not applicable
Auto-ignition Temperature	No data available
Decomposition Temperature	No data available
Upper explosive limit	No data available
Lower explosive limit	No data available
Flammability (solid, gas)	No data available

10. STABILITY AND REACTIVITY

Reactivity
Data is not available

Chemical Stability
Stable under normal conditions.

Possibility of hazardous reactions
Hazardous polymerization will not occur.

Conditions to Avoid
Heat - high temperatures

Incompatible Materials
Strong oxidizers

Hazardous Decomposition Products
Oxides of carbon – organic compounds

11. TOXICOLOGICAL INFORMATION

See product insert and/or packaging for additional information.

Acute Toxicity

Ivermectin:
Oral LD50 (rat) 50 mg/kg
Oral LD50 (human) >15mg/kg
Dermal LD50 406 mg/kg (rabbit)
Praziquantel
Oral LD50 (rat) 2840 mg/kg
Dermal LD50 (rat) >2000 mg/kg

Specific Target Organ Toxicity (STOT) – single exposure

Ivermectin: At high doses in humans and animals vomiting, tachycardia, blood pressure fluctuation, CNS effects (somnolence, ataxia) and visual disturbances have been observed. Higher doses may cause death due to respiratory depression.
Praziquantel: Acute overexposure (ingestion) may cause dizziness, headache, drowsiness, malaise, abdominal pain.

Specific Target Organ Toxicity (STOT) – repeat exposure

Ivermectin: No data available
Praziquantel: Chronic overexposure may cause nausea, lethargy, diarrhea, itching, fever and rash.

Serious Eye damage/Irritation

Ivermectin: Slightly irritating to eyes in rabbit tests.
Praziquantel: Not irritating to eyes in rabbit studies.

Skin Corrosion/Irritation

Ivermectin: Non-irritating in animal studies.
Praziquantel: Not irritating to skin in rabbit studies.

Respiratory or Skin Sensitization

Ivermectin: Hypersensitivity reactions have been reported in humans.
Praziquantel: Not sensitizing to skin in guinea pig study.

Carcinogenicity

Titanium Dioxide: IARC Overall Evaluation is 2B (Possibly carcinogenic to humans) IARC evaluation guidelines consider the generation of tumors, in 2 different studies within the same animal species, to be adequate criteria for an assessment of sufficient evidence. The conclusions of several epidemiology studies on more than 20000 TiO_2 industry workers in Europe and the USA did not suggest a carcinogenic effect of TiO_2 dust on the human lung. Mortality from other chronic diseases, including other respiratory diseases, was also not associated with exposure to TiO_2 dust. Based upon these studies, titanium dioxide is not expected to cause lung cancer or chronic respiratory diseases in humans at concentrations experienced in the workplace.

Praziquantel: Long term studies in rats and golden hamsters did not reveal any carcinogenic effect.

Germ Cell Mutagenicity

Ivermectin: Negative in the AMES Assay, and in a mouse lymphoma mutation assay. In addition, it did not induce unscheduled DNA synthesis in a human fibroblast cell culture, suggesting that it does not damage DNA.
Praziquantel: Negative results for in vivo and in vitro animal studies.

11. TOXICOLOGICAL INFORMATION

Reproductive Toxicity
Ivermectin: Teratogenic in rats, rabbit and mice at or near materno-toxic dose levels. The abnormalities are limited mainly to cleft palate.
Praziquantel: Studies in rats and rabbits have shown no evidence of impaired fertility or harm to the fetus. An increase of the abortion rate was found in rats at three times the single human therapeutic dose.

Aspiration Hazard
Not an aspiration hazard.

12. ECOLOGICAL INFORMATION

Ecotoxicity
Ivermectin:
LC50 (Trout) 0.003mg/l 96hr
LC50 (Daphnia magna) 0.000025mg/l 48hr

Mobility in soil
Ivermectin: Ivermectin is metabolized in the soil. Water solubility is limited and it binds to soil very tightly. It does not bioconcentrate in fish and is not taken up from soil into plants.

Persistence/Degradability
Ivermectin: Slow biodegradation. Photodegrades rapidly.

Bioaccumulative Potential
No relevant studies identified.

Other adverse effects
No relevant studies identified.

13. DISPOSAL CONSIDERATIONS

Dispose of the syringe in an approved landfill or by incineration.

14. TRANSPORT INFORMATION

Contact supplier for transport information.

15. REGULATORY INFORMATION

United States TSCA Inventory
This product is excluded from the US EPA Toxic Substance Control Act and is regulated under the Food, Drug and Cosmetic Act.

Canada DSL Inventory
All ingredients have not been verified for listing on the Domestic Substance List (DSL).

15. REGULATORY INFORMATION

SARA Title III Sect. 311/312 Categorization
None

SARA Title III Sect. 313
This product does not contain any chemicals listed in Section 313 at or above de minimis concentrations.

16. OTHER INFORMATION

Legend
ACGIH: American Conference of Governmental Industrial Hygienists
BOD: Biological Oxygen Demand
CAS#: Chemical Abstracts Service Number
DSL: Domestic Substances List
ECHA: European Chemicals Agency
EPA: Environmental Protection Agency
FIFRA: Federal Insecticide, Fungicide and Rodenticide Act
HDT: Highest Dose Tested
HMIS: Hazardous Materials Identification System IARC: International Agency for Research on Cancer
LC50: Lethal Concentration 50%
LD50: Lethal Dose 50%
LOEL: Lowest Observed Effect Level
N/A: Denotes no applicable information found or available
NFPA: National Fire Protection Association
NOEL: No Observed Effect Level
OSHA: Occupational Safety and Health Administration
PEL: Permissible Exposure Limit
TSCA: Toxic Substances Control Act
SARA: Superfund Amendments and Reauthorization Act
SDS: Safety Data Sheet
STEL: Short Term Exposure Limit
WHMIS: Workplace Hazardous Materials Information System
TLV: Threshold Limit Value
TSCA: Toxic Substance Control Act

Revision Date: March 3, 2020
Replaces: December 21, 2015
Changes made: Update to emergency numbers and section 15.

Information Source and References
This SDS is prepared by Hazard Communication Specialists based on information provided by internal company references.

Prepared By: EnviroNet LLC.

16. OTHER INFORMATION

The information and recommendations presented in this SDS are based on sources believed to be accurate. Virbac AH, Inc. assumes no liability for the accuracy or completeness of this information. It is the user's responsibility to determine the suitability of the material for their particular purposes. In particular, we make NO WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED, with respect to such information, and we assume no liability resulting from its use. Users should ensure that any use or disposal of the material is in accordance with applicable Federal, State, and local laws and regulations.